Increased β-adrenergic inotropy in ventricular myocardium from Trpm4-/- mice.
BACKGROUND
The Trpm4 gene has recently been associated with several disorders, including cardiac conduction diseases and Brugada syndrome. Transient receptor potential member 4 (TRPM4) proteins constitute Ca2+ -activated, but Ca2+ -impermeable, nonselective cation channels and are expressed both in atrial and in ventricular cardiomyocytes. The physiological function of TRPM4 in the heart remains, however, incompletely understood.


OBJECTIVE
To establish the role of TRPM4 in cardiac muscle function.


RESULTS
We used TRPM4 knockout mice and performed patch-clamp experiments, membrane potential measurements, microfluorometry, contractility measurements, and in vivo pressure-volume loop analysis. We demonstrate that TRPM4 proteins are functionally present in mouse ventricular myocytes and are activated on Ca2+ -induced Ca2+ release. In Trpm4(-/-) mice, cardiac muscle displays an increased β-adrenergic inotropic response both in vitro and in vivo. Measurements of action potential duration show a significantly decreased time for 50% and 90% repolarization in Trpm4(-/-) ventricular myocytes. We provide evidence that this change in action potential shape leads to an increased driving force for the L-type Ca2+ current during the action potential, which explains the altered contractility of the heart muscle.


CONCLUSIONS
Our results show that functional TRPM4 proteins are novel determinants of the inotropic effect of β-adrenergic stimulation on the ventricular heart muscle.
From the Department of Molecular and Cellular Medicine, Laboratory of Ion Channel Research, Leuven, Belgium (I.M., M.K., G.J., T.V., B.N., R.V.); Research Unit of Experimental Cardiac Surgery, KU Leuven, Leuven, Belgium (G.V.d.M., P.H.); Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Germany (I.M., J.E.C.L., S.U., M.F.); and Experimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, Homburg, Germany (J.E.C.L., V.F., M.F.).
Ilka
I
Mathar
Miklos
M
Kecskes
Gerry
G
Van der Mieren
Griet
G
Jacobs
Juan E
JE
Camacho Londoño
Sebastian
S
Uhl
Veit
V
Flockerzi
Thomas
T
Voets
Marc
M
Freichel
Bernd
B
Nilius
Paul
P
Herijgers
Rudi
R
Vennekens
D000200:Action Potentials; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D056966:Excitation Contraction Coupling / Q000187:drug effects; D005786:Gene Expression Regulation; D006352:Heart Ventricles / Q000187:drug effects* / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology*; D007700:Kinetics; D051379:Mice; D057507:Mice, 129 Strain; D018345:Mice, Knockout; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D050053:TRPM Cation Channels / Q000172:deficiency* / Q000235:genetics
D000318:Adrenergic beta-Agonists; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D002316:Cardiotonic Agents; D011943:Receptors, Adrenergic, beta; D050053:TRPM Cation Channels; C476766:TRPM4 protein, mouse; D007545:Isoproterenol; D002118:Calcium
TRPM4 protein, mouse; action potentials; calcium signaling; excitation contraction coupling; ion channels; mice, knockout